PubMed Health⌕ Search

Biomedical subjects

Z L Rossetti

Publications and source records attributed to Z L Rossetti.

At least 19 recordsLinked to original sources
PubMed1992

Marked inhibition of mesolimbic dopamine release: a common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats.

Withdrawal of rats from chronic ethanol, morphine, cocaine and amphetamine resulted in a marked reduction in extracellular dopamine (DA) concentration in the ventral striatum as measured by microdialysis. Following ethanol and naloxone-precipitated morphine withdrawal, the time course of DA reduction paralleled that of the withdrawal symptomatology. On the other hand, following discontinuation of chronic cocaine, DA reduction was delayed by over 24 h but persisted for several days. After amphetamine withdrawal the fall in DA occurred more rapidly but the reduction also persisted for several days. The administration of the NMDA receptor antagonist, MK-801, to rats withdrawn from chronic ethanol, morphine or amphetamine, but not from chronic cocaine, readily reversed the fall in DA output. The reduction in extracellular DA during ethanol withdrawal was also reversed by SL 82.0715, another NMDA receptor antagonist.

Amphetamine↗
PubMed1992

Marked decrease of A10 dopamine neuronal firing during ethanol withdrawal syndrome in rats.

The electrophysiological activity of mesoaccumbens dopaminergic neurons was monitored during the ethanol-withdrawal syndrome in ethanol-dependent and in control rats. Spontaneous firing was reduced by about half in ethanol-dependent rats as compared to controls. Likewise, the number of spikes/burst was also reduced in ethanol-dependent rats. These results are consistent with the reduction in dopamine release observed during ethanol-withdrawal syndrome and may provide the basis for the aversive effects of the ethanol-withdrawal syndrome.

Animals↗
PubMed1992

Alcohol withdrawal in rats is associated with a marked fall in extraneuronal dopamine.

Withdrawal of rats from chronic ethanol (2-5 g/kg, every 6 hr for 6 days) resulted in withdrawal symptomatology and dramatic fall in extracellular dopamine (DA) in the ventral striatum as measured by microdialysis. The changes in DA output paralleled the withdrawal symptomatology and both phenomena were reversed by a challenge ethanol dose (5 g/kg orally). The results suggest that the decrease in DA output may be responsible for the aversive symptoms of withdrawal.

3,4-Dihydroxyphenylacetic Acid↗
PubMed1992

Lack of tolerance to ethanol-induced stimulation of mesolimbic dopamine system.

Rats maintained for 10 days on a 10% ethanol solution as the sole source of fluid developed marked tolerance to ethanol-induced loss of righting reflex, but no tolerance to the stimulatory effects on mesolimbic dopaminergic system. An ethanol challenge stimulated both the electrical activity of A10 dopaminergic cells and dopamine output in the ventral striatum of behaviourally tolerant animals and of controls to the same extent. These results are compatible with the hypothesis that an increased dopamine neurotransmission in the limbic system participates in the reinforcing effect of ethanol.

3,4-Dihydroxyphenylacetic Acid↗
PubMed1992

Biphasic effect of ethanol on noradrenaline release in the frontal cortex of awake rats.

Ethanol elicited a biphasic effects on the extracellular noradrenaline (NA) concentrations in the rat frontal cortex, as assessed by microdialysis in awake animals. A low dose of ethanol (0.2 g/kg i.p.) raised NA output to about 160% of baseline levels. In contrast, a dose of 2 g/kg inhibited NA output to about 70% of pre-drug levels. These results suggest that the decrease in cortical NA output may reflect the sedative-hypnotic properties of ethanol at high doses, whereas the stimulation of extraneuronal NA may represent a biochemical correlate of the arousal and increased alertness elicited by low doses of ethanol.

Animals↗
PubMed1991

Repeated treatment with imipramine potentiates cocaine-induced dopamine release and motor stimulation.

The stimulatory effect of cocaine on locomotor activity and on dopamine efflux from the ventral striatum was studied in rats chronically treated with the antidepressant imipramine. Chronic imipramine (20 mg/kg per day for 3 weeks) potentiated by about 2-fold cocaine-stimulated motor activity and extracellular dopamine concentrations. The results indicate that chronic imipramine facilitates mesolimbic dopamine neurotransmission by potentiating the mechanism which is thought to mediate the rewarding effects of cocaine.

3,4-Dihydroxyphenylacetic Acid↗
PubMed1991

Interaction of 1-methyl-4-phenylpyridinium ion and tyramine with a site putatively involved in the striatal vesicular release of dopamine.

The neurotoxin MPP+ potently inhibited the striatal binding of [3H]-tyramine, a putative marker for the vesicular transporter of dopamine, and provoked a massive in vivo release of striatal dopamine. Tetrabenazine, an established ligand for the vesicular catecholamine carrier, potently inhibited [3H]-tyramine binding, tyramine-provoked striatal efflux of dopamine and the fast component of MPP(+)-induced dopamine release. It is concluded that MPP+ in the striatum, besides interacting with additional intracellular targets, avidly binds at a vesicular site functionally involved with the outward transport of dopamine.

Animals↗
PubMed1990

Calcium receptor antagonists modify cocaine effects in the central nervous system differently.

The effect of different calcium antagonists on cocaine-induced dopamine (DA) release in the striatum, as measured by brain microdialysis in freely moving rats, and on cocaine-induced motor stimulation was studied. While two dihydropyridine calcium antagonists, nimodipine (20 mg/kg) and isradipine (2.5 mg/kg), prevented cocaine-induced DA release and motor stimulation, the diphenylalkylamine-type calcium antagonist flunarizine (20 mg/kg) strongly potentiated both effects of cocaine. Moreover, two calcium antagonists, verapamil (20 mg/kg) and diltiazem (20 mg/kg), were ineffective. The results indicate that various classes of calcium antagonists differ in their interaction with the effects of cocaine in the CNS and suggest that dihydropyridine calcium channel antagonists might be clinically useful for the treatment of cocaine abuse.

Amphetamine↗
PubMed1990

Flunarizine potentiates cocaine-induced dopamine release and motor stimulation in rats.

Pretreatment with flunarizine (20 mg/kg), a diphenylalkylamine calcium channel antagonist, markedly potentiated cocaine (10 mg/kg)-induced dopamine (DA) output from the ventral striatum, as measured by microdialysis in freely moving rats. Moreover, flunarizine enhanced cocaine-induced motor stimulation. Pretreatment with the D2 receptor antagonist (-)-sulpiride (25 mg/kg) potentiated cocaine-induced DA output but, unlike flunarizine, inhibited cocaine-induced motor stimulation. When added to striatal membrane preparations, flunarizine displaced [3H]spiperone binding with a Ki of about 100 nM. Since recent evidence indicates that the effects of cocaine are calcium-dependent and are prevented by dihydropyridine calcium antagonists, these findings suggest that the paradoxical potentiating effect of flunarizine is probably due to an interaction with the DA system and is not due to its calcium antagonist property.

Animals↗
PubMed1990

The non-competitive NMDA-receptor antagonist MK-801 prevents the massive release of glutamate and aspartate from rat striatum induced by 1-methyl-4-phenylpyridinium (MPP+).

The concentrations of dopamine (DA) and of the excitatory amino acids (EAAs) glutamate (Glu) and aspartate (Asp) were measured in dialysates from the striatum of awake rats in order to study the link between the release of DA and of EAAs induced by the infusion of 1-methyl-4-phenylpyridinium ion (MPP+). DA and EAAs were detected simultaneously by HPLC-EC. The infusion of MPP+ at the concentration of 1 mM elevated DA levels in the perfusates, but did not affect EAA release. However, MPP+ at 10 mM maximally stimulated Glu and Asp release to 230- and 68-fold of baseline, respectively. In this condition, pretreatment with the N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 (5 mg/kg, i.p.) prevented the MPP(+)-induced EAA release. In contrast, MK-801 had no effect on DA release induced either by 1 or 10 mM MPP+. These results suggest that MPP(+)-induced DA and EAA release are independently regulated processes. In addition, the finding that MK-801 inhibits MPP(+)-induced EAA release suggests that EAAs may act on NMDA receptors to stimulate their own release through a positive-feedback mechanism.

1-Methyl-4-phenylpyridinium↗
PubMed1990

Brain dialysis and dopamine: does the extracellular concentration of dopamine reflect synaptic release?

We considered the drug-induced circling behaviour of rats monolaterally lesioned with kainic acid (KA) as a marker of the dopamine (DA) concentration in the synaptic space. D-Amphetamine produced a dose-related increase in the DA concentration of the dialysate from an intact striatum and a proportional number of ipsilateral circlings. Pargyline or L-dihydroxyphenylalanine (L-Dopa), alone or in combination with benserazide, increased the concentration of DA to a similar or even higher level than d-amphetamine, but failed to elicit a circling response. Apomorphine given after these drugs at the peak of DA accumulation always induced circling behaviour. The results suggest that released DA may undergo different inactivation processes before reaching the dialysis probe, and that these processes may be differentially affected by drug treatments. Alternatively, it may be suggested that DA can be released into the synaptic space, in a functional manner, or into the interstitial fluid, from where it cannot reach the synaptic receptors.

Animals↗
PubMed1990

Stress increases noradrenaline release in the rat frontal cortex: prevention by diazepam.

Foot-shock produced a more than 2-fold increase in noradrenaline (NA) release from the frontal cortex of freely moving rats. The effect of acute stress was almost completely prevented by the administration of diazepam (5 mg/kg i.p.). Diazepam alone inhibited cortical NA release, the maximal inhibition (-57%) being observed 90 min after the injection. Cortical NA release therefore appears to be a reliable index of central noradrenergic activity in response to stressful conditions.

Animals↗